Table 3.

Prognostic factors for PFS, and OS in the multivariate analyses

	PFS			OS
	HR	95% CI	P value	HR	95% CI	P value
Sex
Female
Male
Age
≥ 70	Excluded by factor selection with step-wise method			Excluded by factor selection with step-wise method
< 70
Enhancement
Yes	Excluded by factor selection with step-wise method			Excluded by factor selection with step-wise method
No
KPS
≥ 80	0.20	0.1–0.41	< 0.0001	0.23	0.09–0.62	0.004
< 80	Reference			Reference
LN mean
≥ 2.46				Excluded by factor selection with step-wise method
< 2.46
LN max
≥ 4.03				Reference
< 4.03				0.24	0.08–0.71	0.01
Histology
DA	Excluded by factor selection with step-wise method			Reference
AA				5.3	1.23–22.8	0.025
GBM				11.52	2.27–58.47	0.0032
IDH status
Mutant	Excluded by factor selection with step-wise method			Reference
Wild-type				14.06	1.81–109.2	0.011
TERT promoter
Mutant	Excluded by factor selection with step-wise method
Wild-type
MGMT
Met
Un-Met
Adjuvant therapy
None				Excluded by factor selection with step-wise method
CRT
RT only
Chemo only
Treatment
Biopsy
PR
STR, GTR

KPS Karnofsky performance status, LN lesion-to-contralateral normal brain tissue, DA diffuse astrocytoma, AA anaplastic astrocytoma, GBM glioblastoma, IDH isocitrate dehydrogenase, TERT telomerase reverse transcriptase, MGMT O⁶-methylguanine-DNA-methyltransferase, Met methylation, CRT chemoradiotherapy, RT radiation therapy, Chemo chemotherapy, PR partial resection, STR subtotal resection, GTR gross total resection, PFS progression-free survival, HR hazard ratio, CI confidence interval, OS overall survival.

P values in bold font are statistically significant.